• Skip to primary navigation
  • Skip to main content
  • Skip to footer
BOMSS

BOMSS

British Obesity & Metabolic Surgery Society

  • Home
  • About BOMSS
    • About BOMSS
      • Overview
      • Vision, mission and values
      • Equality, diversity and inclusion
    • Who we are
      • Trustees
      • Council
      • Patient Safety Committee
      • Endoscopy Committee
      • IHP Committee
      • NBSR
    • Membership
  • Healthcare Professionals
    • Clinical Resources
  • ASM 2023
    • Annual Scientific Meeting 2022
    • Annual Scientific Meeting 2021
  • Events
  • Contact
  • About
        • Overview
        • Who we are
          • Council
          • Trustees
          • Patient Safety Committee
          • Endoscopy Committee
          • IHP Committee
          • NBSR
        • Membership
        • Equality, diversity and inclusion
        • Vision, mission and values
        • Contact
  • Patient information
    • What is obesity?
    • How is obesity measured?
    • Obesity-linked health problems
    • Managing obesity
      • Your mindset
      • Medication
      • NHS Tiered Care Weight Management Pathway
      • Bariatric and Metabolic Surgery
        • Adjustable Gastric Banding
        • Gastric Bypass – Roux en Y Gastric Bypass
        • Sleeve Gastrectomy
        • One-anastomosis (Mini) Gastric Bypass (OAGB)
        • Bilio-Pancreatic Diversion With Duodenal Switch (BPD-DS)
        • Bariatric surgery for people with type 2 diabetes (T2D)
    • Accessing Tier 4 Services
  • ASM
    • ASM 2023
    • ASM 2022
    • ASM 2021
    • Event calendar
  • Healthcare professionals
    • Clinical Resources

Invitation to National Survey: Restarting Direct Oral Anticoagulants (DOACs) after Bariatric Surgery

You are here: Home / News / Invitation to National Survey: Restarting Direct Oral Anticoagulants (DOACs) after Bariatric Surgery

13/02/2023

The risk of malabsorption of DOAC after bariatric surgery is a cause of concern for health professionals looking after patients who have undergone bariatric surgery. The extent to which bariatric surgery alters the pharmacokinetics and pharmacodynamics of DOAC is unknown.

We are carrying out this survey to explore how bariatric surgical units across the UK are restarting DOACs after bariatric surgery.

We would appreciate if you could complete this short survey which is anonymous and will only take few minutes.

Please click on the link below which will take you straight to the survey:

Restarting DOACs after Bariatric Surgery Survey

Kind Regards,

M. Chatzikonstantinou, RCSEng post CCT Bariatric Fellow
W. Mon, Consultant Bariatric Anaesthetist
R. Batterham, Consultant Bariatric Physician
M. Adamo, Consultant Bariatric Surgeon
UCLH Bariatric centre for weight management and metabolic surgery

Category iconNews

Footer

Quick links

  • Home
  • About
  • ASM
  • Events
  • Contact
  • Privacy policy

Contact

British Obesity & Metabolic Surgery Society CIO (BOMSS)
C/O Executive Business Support
Davidson Road
City Wharf
Lichfield
WS14 9DZ

[email protected]

01543 442 195

Copyright © 2023 British Obesity & Metabolic Surgery Society CIO    I

I   Registered charity No: 1192184